Relmada Therapeutics (RLMD) Non Operating Income (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Non Operating Income data on file, last reported at $409798.0 in Q1 2026.

• Non Operating Income for Q1 2026 came in at $409798.0, down 37.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (down 57.02% YoY), and the FY2025 annual result was $1.7 million, down 56.16% from the prior year.
• Non Operating Income slipped to $409798.0 in Q1 2026 per RLMD's latest filing, from $465352.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $5.6 million in Q2 2022 and troughed at -$1.4 million in Q1 2022.
• A 5-year average of $891312.7 and a median of $690580.0 in 2023 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 6292.38% in 2022 and fell as far as 1536.53% in 2022.
• A 5-year view of Non Operating Income shows it stood at $758055.0 in 2022, then soared by 119.53% to $1.7 million in 2023, then sank by 74.86% to $418418.0 in 2024, then climbed by 11.22% to $465352.0 in 2025, then retreated by 11.94% to $409798.0 in 2026.
• Business Quant data shows RLMD's Non Operating Income at $409798.0 in Q1 2026, $465352.0 in Q4 2025, and $235850.0 in Q3 2025.